Amphiphilic functional nano-composite as well as preparation method and application thereof
Through amphiphilic functional nanocomplex loaded chemotherapy drugs and CDT promoters, combined with Fc-catalyzed Fenton reaction, the problems of low bioavailability and great side effects in tumor treatment are solved, and high efficiency in deep tumors are achieved Suppression effect.
Patent Information
- Application Number
- CN202411072532.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-22
AI Technical Summary
In tumor treatment, existing chemotherapy drugs have problems such as low bioavailability, poor tumor permeability, easy to produce multidrug resistance and uncontrolled side effects, which limit their therapeutic effects, especially in deep hypoxic tumors. It is difficult to effectively inhibit tumor growth during treatment.
Develop an amphiphilic functional nanocomplex that loads chemotherapy drugs and CDT promoters through emulsification-solvent volatilization, utilizes the hydrophobic core of the amphiphilic polymer to provide a natural drug-loading environment, and combines Fc-catalyzed Fenton reactions to improve The H2O2 concentration in tumor cells enhances chemical kinetic efficacy and improves the therapeutic effect of drugs through an acid-dependent release mechanism.
The nanocomplex is stable in the body and has longer blood circulation. It can effectively release drugs in a slightly acidic environment of tumors, increase the H2O2 concentration in tumor cells, enhance the anti-tumor effect of Fenton reaction, significantly inhibit tumor growth, and reduce the The toxic side effects of chemotherapy drugs.
Smart Images

Figure CN118987237A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of traditional Chinese medicine preparations, and in particular to an amphiphilic functional nanocomposite and a preparation method and application thereof. Background Art
[0002] Chemodynamic therapy (CDT) of tumors uses drugs to convert endogenous H2O2 into highly cytotoxic reactive oxygen species (ROS) through the Fenton reaction to kill tumor cells. Because it is independent of external stimuli and local oxygen concentration, CDT has become an ideal candidate therapy for inhibiting the growth of deep hypoxic tumors. The key to further development of CDT is how to produce sufficient endogenous H2O2 at the tumor site.
[0003] Anthracyclines are a class of chemotherapy drugs derived from Streptomyces peucetius var. caesius. Anthracyclines can be used in combination with other chemotherapy drugs and molecular targeted drugs. Combination therapy based on anthracyclines is usually the standard first-line treatment. Anthracyclines, including doxorubicin, epirubicin, daunorubicin and aclarubicin, are widely used in the treatment of hematological malignancies and solid tumors. Anthracyclines have a broad anti-tumor spectrum, strong anti-tumor effects, definite efficacy, and are indispensable, but can cause toxic side effects such as hair loss, bone marrow suppression and cardiac toxicity.
[0004] At present, the use of single chemotherapy drugs has disadvantages such as low bioavailability, poor tumor permeability, easy to produce multidrug resistance and uncontrolled side effects, which seriously reduce the therapeutic effect (J Nanostruct Chem 2024, 14 (1): 1-19). Combination therapy has emerged as an emerging treatment method, among which chemotherapy and chemodynamics (CDT) combined therapy has shown good synergistic effects in inhibiting tumor growth (Adv Sci 2020, 7 (17): 2001060; J Mater Chem B. 2017, 5 (7): 1507-1517; Biomaterials 2021, 275, 120962). Based on the strategy of enhancing CDT by increasing the concentration of intracellular H2O2, CDT-promoting drugs were selected for combination with anthracyclines. However, anthracyclines have serious cardiotoxic, hepatotoxic and renal toxicity, which seriously limits their practical application (Acta Biomater 2019, 94, 469-481; JACC Cardio Oncol 2021, 3(3): 428-440). Summary of the invention
[0005] In order to solve the above technical problems, the present invention provides an amphiphilic functional nanocomposite and a preparation method and application thereof. The amphiphilic functional nanocomposite is evenly dispersed, has a good morphology, has a high negative charge on the surface, and can stably exist in an in vivo environment simulation fluid; has a longer blood circulation; when reaching the slightly acidic environment of the tumor, the charge is converted into a positive charge, and it is easier to bind to the negatively charged cell membrane; the release effect shows that the drug release of the amphiphilic functional nanocomposite is time- and acid-dependent.
[0006] The present invention is achieved through the following technical solutions: On the one hand, an amphiphilic functional nanocomposite is provided, which is constructed by using an amphiphilic polymer as a carrier and loading chemotherapeutic drugs and CDT-promoting drugs through an emulsification-solvent evaporation method; wherein the amphiphilic polymer has a structure shown in the following formula (I):
[0007]
[0008] In formula (I), n, x, y, m, and k are all natural numbers, n=10-500, x=100-300, y=150-400, m=1-500, and k=1-500;
[0009] R is H, for (Glucan) or (Mannan).
[0010] Through the above technical scheme, chemotherapeutic drugs and CDT-promoting drugs act synergistically on pancreatic cancer treatment through chemotherapy and CDT. The hydrophobic core in the amphiphilic polymer provides a natural drug-carrying environment for poorly soluble drugs. Based on the fact that both the selected chemotherapeutic drugs and CDT-promoting drugs can increase the concentration of H2O2 in tumor cells, a large amount of highly toxic ·OH is produced through the Fenton reaction catalyzed by the Fc coupled to the carrier, inducing tumor cell death.
[0011] Although tumor cells have high levels of hydrogen peroxide, H2O2 in the tumor is still insufficient to produce sufficient ·OH to achieve satisfactory CDT efficacy. In addition, the concentration of glutathione (GSH) in tumor tissue is high, which, as an important antioxidant in cells, can scavenge the produced ·OH and weaken the CDT effect. Therefore, the simultaneous introduction of H2O2 supply and GSH elimination functions in one nanoplatform is beneficial to enhance the CDT effect.
[0012] Among them, chemotherapy drugs such as DOX, dihydroartemisinin, and cisplatin can increase the concentration of H2O2 inside the tumor through redox reactions.
[0013] CDT promoting drugs are drugs that can produce a large amount of H2O2 to promote CDT reactions.
[0014] The CDT reaction process is as follows:
[0015] Fe 3+ +GSH→Fe 2+ +GSSG
[0016] Fe 2+ +H2O2→Fe 3+ + OH+OH -
[0017] The drug system, through Fe 3+ Reacts with GSH, thereby reducing the intracellular GSH content; through chemotherapy drugs that can increase the H2O2 concentration and CDT-promoting drugs (increasing the H2O2 concentration), the CDT efficacy can be improved.
[0018] Furthermore, in step 1), the mass ratio of the amphiphilic polymer:chemotherapeutic drug:CDT promoting drug is 5-20:0.02-0.1:1.
[0019] Furthermore, the chemotherapy drug is selected from one or more of DOX, dihydroartemisinin, and cisplatin. Preferably, the chemotherapy drug is DOX.
[0020] Furthermore, the CDT promoting drug is selected from one or more of VP, β-lapachone, and juglone. Preferably, the CDT promoting drug is VP.
[0021] The present invention co-loads ascorbyl palmitate (VP) and doxorubicin (DOX) into the interior of an amphiphilic functional nanocomposite (VDF NPs). After reaching the tumor site, the high local concentration of VP and DOX can rapidly increase the concentration of H2O2 in tumor cells, and further generate highly toxic ·OH through the Fenton reaction catalyzed by ferrocene coupled to the carrier, and is used in the treatment of pancreatic cancer in synergistic chemotherapy and chemodynamic therapy. The novel nanocarrier is synthesized by introducing a hydrophilic side chain carboxymethyl chitosan (CMCS) and a hydrophobic side chain ferrocene derivative (Fc) into dextran (Dex) to synthesize an amphiphilic functional carrier Fc-Dex-CMCS.
[0022] A method for preparing the above-mentioned amphiphilic functional nanocomposite is also provided, and the specific steps are as follows:
[0023] Step 1) Synthesis of amphiphilic polymer;
[0024] Step 2) dissolving the amphiphilic polymer obtained in step 1) in pure water, dissolving it with ultrasonic aid until it is completely dissolved, cooling it to room temperature, and then adding an organic solvent containing a chemotherapeutic drug and a CDT-promoting drug to react while stirring in an ice bath, the reaction temperature is 25-100° C., and the reaction time is 4-72 hours;
[0025] Step 3) removing the organic solvent from the reactant obtained in step 2), ultrasonicating, and performing two-stage centrifugation to obtain an amphiphilic functional nanocomposite.
[0026] Specifically, based on the synthesis of amphiphilic polymer (FDC), FDC is dissolved in pure water and ultrasonically assisted. After complete dissolution, it is cooled to room temperature. Under ice bath stirring conditions, an organic solvent containing ascorbyl palmitate (VP) and doxorubicin (DOX) is slowly added dropwise to the above solution. After stirring for reaction, the organic solvent is removed on a rotary evaporator. Ultrasound is used to promote particle dispersion. 2 mL is placed in an ultrafiltration centrifuge tube (relative molecular weight cutoff: 3KD), and then placed in a desktop low-temperature centrifuge. Free VP and DOX in the solution are separated by centrifugation to obtain VDF NPs.
[0027] Preferably, the heating dissolution temperature of the amphiphilic polymer (FDC) is 25-100°C;
[0028] Preferably, the molar ratio of FDC to VP is 5-20:1, and the molar ratio of VP to DOX is 10-50:1;
[0029] Preferably, the organic solvent is one of methanol or ethanol;
[0030] Preferably, the reaction temperature is 25-100°C and the reaction time is 4-72h.
[0031] Through the above technical scheme, Fc-Dex-CMCS was used as a carrier and the emulsification-solvent evaporation method was used to prepare VP / DOX@FDC NPs. The specific reaction formula is as follows:
[0032]
[0033] The effects of the above preparation method on encapsulation efficiency and drug loading are as follows:
[0034]
[0035] Further, in step 1), the process of synthesizing the amphiphilic polymer is as follows:
[0036] Step 1: Synthesis of DeX-CHO;
[0037] Step 2: Synthesis of Dex-CMCS conjugates;
[0038] Step 3: Synthesis of CMCS-Dex-CHO;
[0039] Step 4: Synthesis of 6-aminohexanoylferrocene;
[0040] Step 5: Synthesis of Fc-Dex-CMCS conjugate.
[0041] Furthermore, in the first step, the raw material contains an oxidant, and the molar ratio of the dextran (Dex) to the oxidant is 1:1-10; the molecular weight of the dextran (Dex) is 2-100 kDa.
[0042] Specifically, dextran (Dex) was dissolved in pure water, ultrasonicated to fully dissolve it and remove the air in the solution, and slowly added with an oxidant aqueous solution under N2 protection, and stirred for reaction. The solution after the reaction was poured into an 8-10kD dialysis bag and dialyzed 4 times, 12h / time. After the dialysis, it was dried with a freeze dryer to obtain Dex-CHO.
[0043] Preferably, the oxidant is one of lead acetate, sodium periodate or periodic acid;
[0044] Preferably, the reaction temperature is 25-100°C, and the reaction time is 4-72h.
[0045] Furthermore, in the second step, the raw materials include carboxymethyl chitosan and a reducing agent, the molar ratio of the carboxymethyl chitosan:Dex-CHO is 0.5-5:1; the molar ratio of the carboxymethyl chitosan and the reducing agent is 1:1-10; and the molecular weight of the carboxymethyl chitosan is 2-100 kDa.
[0046] Specifically, carboxymethyl chitosan (CMCS) is dissolved in a solvent, heated and ultrasonically promoted to fully dissolve, and air is removed by ultrasonication. After cooling, the above Dex-CHO is slowly added under N2 protection, stirred for reaction, and a reducing agent is added for reduction. The reduced solution is poured into a 8-10kD dialysis bag and dialyzed 4 times, 12h / time. After the dialysis is completed, it is dried with a freeze dryer to obtain Dex-CMCS.
[0047] Preferably, the CMCS ultrasonic heating temperature is 25-100°C;
[0048] Preferably, after adding the reducing agent, the reaction temperature is 25-100° C. and the reaction time is 4-72 h.
[0049] Preferably, the solvent is one of DMF, DMSO or isopropanol.
[0050] Preferably, the reaction temperature of carboxymethyl chitosan and Dex-CHO is 25-100° C., and the reaction time is 4-72 h.
[0051] Preferably, the reducing agent is lithium aluminum tetrahydride, sodium borohydride or aluminum isopropoxide;
[0052] Furthermore, in the third step, the raw material contains an oxidant, and the molar ratio of Dex-CMCS to the oxidant is 1:20-1:200.
[0053] Specifically, Dex-CMCS was dissolved in pure water, heated to promote full dissolution, and air was removed by ultrasound. After cooling to room temperature, an aqueous solution of an oxidant was slowly added under N2 protection, and the reaction was stirred. The solution after the reaction was poured into a 100-500D dialysis bag and dialyzed 4 times, 12 hours per time. After the dialysis, it was dried with a freeze dryer to obtain CMCS-Dex-CHO.
[0054] Preferably, the dissolution temperature of the Dex-CMCS is 25-100°C;
[0055] Preferably, the oxidant is one of lead acetate, sodium periodate or periodic acid;
[0056] Preferably, the reaction temperature is 25-100°C and the reaction time is 4-72h.
[0057] Furthermore, in the fourth step, the raw materials include Boc-6-aminocaproic acid and ferrocene, and the molar ratio of Boc-6-aminocaproic acid to ferrocene is 0.5-5:1.
[0058] Specifically, Boc-6-aminocaproic acid is placed in a round-bottom flask, and a dry organic solvent is added under an ice-salt bath condition. After the solution is completely dissolved, thionyl chloride is added, and a thin layer is detected. After sufficient reaction, the solvent and excess thionyl chloride are removed. The obtained product does not need to be further purified, and an organic solvent containing ferrocene is directly added. Under an ice-water bath condition, a catalyst is slowly added until the color of the solution changes to purple-red. Under an ice bath condition, stirring and reacting are continued. After the reaction is completed, pre-cooled pure water is slowly added under an ice bath condition, and the layers are quenched and separated. After the organic layer is spin-dried, it is redissolved in an organic solvent, and trifluoroacetic acid is added to carry out a Boc removal reaction. After the reaction is completed, the solvent is removed, and column chromatography is performed to obtain 6-aminocaproylferrocene.
[0059] Preferably, the molar ratio of Boc-6-aminocaproic acid to thionyl chloride is 0.5:1-5:1; and the reaction time of Boc-6-aminocaproic acid and thionyl chloride is 4-72h.
[0060] Preferably, the reaction solvent of Boc-6-aminocaproic acid and thionyl chloride is one of tetrahydrofuran, dichloromethane or carbon disulfide.
[0061] Preferably, the molar ratio of Boc-6-aminocaproic acid to the catalyst is 0.5:1-1:5;
[0062] Preferably, the catalyst for the reaction with ferrocene is one of aluminum trichloride, zinc chloride, ferric trichloride or titanium tetrachloride;
[0063] Preferably, the solvent used in the reaction with ferrocene is one of tetrahydrofuran, dichloromethane or carbon disulfide.
[0064] Preferably, the reaction time with ferrocene is 4-72h.
[0065] Preferably, the column chromatography conditions after the reaction with ferrocene are ethyl acetate: petroleum ether = 1:10.
[0066] Further, in the fifth step, the molar ratio of CMCS-Dex-CHO to 6-aminohexanoylferrocene is 1:20-200.
[0067] Specifically, CMCS-Dex-CHO is dissolved in an organic solvent, heated and ultrasonicated to fully dissolve it, and after it is completely dissolved, an organic solvent containing 6-aminohexanoylferrocene is slowly added under N2 protection, stirred for reaction, and the resulting solution is poured into a 100-500D dialysis bag, and dialysis is performed 4 times, 12 hours per time. After the dialysis is completed, it is dried using a freeze dryer to obtain the product Fc-Dex-CMCS (FDC).
[0068] Preferably, the dissolution temperature of the CMCS-Dex-CHO is 25-100°C;
[0069] Preferably, the reaction solvent of CMCS-Dex-CHO and 6-aminohexanoylferrocene is one of DMF, DMSO or acetonitrile.
[0070] Preferably, the reaction temperature of the CMCS-Dex-CHO and 6-aminohexanoylferrocene is 25-100° C. and the reaction time is 4-72 hours.
[0071] Finally, a use of the above-mentioned amphiphilic functional nanocomplex in the preparation of a drug for treating solid tumor diseases is provided. Preferably, the solid tumor is pancreatic cancer.
[0072] The above technical scheme relates to the technical field of combined therapeutic drug preparations for pancreatic cancer, and its beneficial effects are as follows: (1) The synthesized functional carrier has good biocompatibility and can co-load VP and DOX to prepare nanomedicine VDF NPs, and has good stability and release effect. (2) VDF NPs can induce cell apoptosis through the ROS pathway and have better in vitro anti-tumor effects compared with free drugs. (3) VDF NPs can exert a stronger anti-pancreatic cancer effect in vivo than free drugs, and the combination of VP and DOX can weaken the toxic side effects of DOX.
[0073] Beneficial Effects
[0074] The present invention synthesizes a functional nanocarrier based on ferrocene tumor microenvironment responsiveness, constructs a drug-loaded nanoparticle that is self-assembled by co-loading VP and DOX, and is characterized by morphology, particle size, Zate potential and PDI. The results show that the nanocomplex is evenly dispersed, has a good morphology, has a high negative charge on the surface, and can stably exist in an in vivo environment simulation fluid. It has a longer blood circulation. When it reaches the slightly acidic environment of the tumor, the charge is converted to a positive charge, which is easier to bind to the negatively charged cell membrane. The release effect shows that the drug release of the nanocomplex is time- and acid-dependent.
[0075] The results of in vitro experiments showed that VP and DOX had good synergistic effects, and compared with free drugs, the nanocomplex was more easily taken up in the same time, which may be due to the excellent particle size of the nanocomplex and the targeting of the hydrophilic side chain carboxymethyl chitosan on the carrier. In addition, both VP and DOX can increase the concentration of H2O2 in tumor cells, and then produce a large amount of highly toxic ·OH through the Fenton reaction catalyzed by the coupled Fc on the carrier, inducing tumor cell death.
[0076] The in vivo anti-tumor effect of VDF NPs (amphiphilic functional nanocomplexes) was investigated using a mouse pancreatic cancer model. The results showed that injection of VDF NPs via the tail vein could effectively inhibit tumor growth without causing systemic toxicity, which was attributed to the combined use of VP and DOX, which could weaken the toxic side effects of DOX without hindering the anti-tumor activity of DOX. In addition, VDF NPs can directly inhibit the expression of the Ki67 gene to inhibit the proliferation of tumor cells, and can also inhibit the activity and expression of GPX4, thereby promoting cell apoptosis through the ROS pathway. BRIEF DESCRIPTION OF THE DRAWINGS
[0077] Figure 1 (A) 1H-NMR spectra (D2O, 500 MHz) of Dex, Dex-CHO, CMCS, CMCS-Dex and CMCS-Dex-CHO; (B) Fourier transform infrared spectra of Dex, Dex-CHO, CMCS, CMCS-Dex and CMCS-Dex-CHO.
[0078] Figure 2 (A) 1H-NMR spectrum of 6-aminohexanoylferrocene (CDCl3, 500 MHz); (B) MS spectrum of 6-aminohexanoylferrocene.
[0079] Figure 3(A) 1H-NMR spectrum of Fc-Dex-CMCS (DMSO, 500 MHz); (B) Fourier transform infrared spectra of CMCS-Dex-CHO, Fc and Fc-Dex-CMCS.
[0080] Figure 4 Characterization of VDF NPs; (A) TEM image of VDF NPs (scale bar: 200nm and 100nm); (B) particle size distribution of VDF NPs; (C) Zeta potential at different pH values; (D) charge reversal diagram of VDF NPs. (Data are expressed as mean ± SD, n = 3)
[0081] Figure 5 : Standard curves of VP and DOX; (A) peak area fitting curve of ascorbyl palmitate at different concentrations; (B) peak area fitting curve of doxorubicin at different concentrations.
[0082] Figure 6 is the stability of VDF NPs; (AC) the changes of particle size, PDI and Zeta potential over time when the nanoparticles are stored in deionized water for 30 days at 4°C; (DF) the changes of particle size, PDI and Zeta potential over time when the nanoparticles are stored in PBS, FBS and DMEM medium containing 10% FBS for 48 h at 37°C and 100 rpm / min.
[0083] Figure 7 In vitro release effect of VDF NPs; (A) Cumulative release percentage of VP in PBS at different time points; (B) Cumulative release percentage of DOX in PBS at different time points.
[0084] Figure 8 Synergistic effect analysis; AC are the effects of VP@FDC NPs, DOX@FDC NPs and VDF NPs on the viability of Pan02 cells, respectively.
[0085] Fig. 9 Cell viability was detected by CCK-8 method; (A) Survival rate of Pan02 cells 24 hours after administration of VP, DOX, FDC, VP / DOX / FDC Mix and VDF NPs; (B) IC50 values of VP / DOX / FDC Mix and VDF NPs on Pan02 cells. (Data are expressed as mean ± SD, n = 3; **P < 0.01)
[0086] Fig.10(A) The mechanism of H2O2 production by VP and DOX, and the cascade effect with Fc; (B) The relative content of intracellular H2O2 in different drug-treated groups. (Data are expressed as mean ± SD, n = 3; compared with Control, *P < 0.05, **P < 0.01);
[0087] Fig.11 (A) Mouse body weight change curve; (B) Tumor volume change curve; (C) Tumor weight; (D) Tumor inhibition rate; (E) Tumor image; (F) Tumor HE image (200×). (Data are expressed as mean ± SD, n = 6; compared with the Model group, *P < 0.05, **P < 0.01, ***P < 0.001; compared with the VP group, #P < 0.05, ##P < 0.01, ###P < 0.001; compared with the DOX group, △△P < 0.01, △△△P < 0.001).
[0088] Fig.12 HE pathological sections of the organs of mice in each group. (200×)
[0089] Fig.13 The effect of each drug group on the blood routine of mice (data are expressed as mean ± SD, n = 6; compared with the Control group, *P < 0.05, **P < 0.01, ***P < 0.001).
[0090] Fig.14 Liver function indexes: (A) ALT and (B) AST levels in serum; renal function indexes: (C) CRE and (D) BUN levels in serum. (Data are expressed as mean ± SD, n = 6; compared with Control, *P < 0.05, **P < 0.01).
[0091] Fig.15 This is Ki67 immunohistochemical antigen staining in mouse tumor tissue. (200×)
[0092] Fig.16 Immunohistochemical staining of GPX4 antigen in mouse tumor tissue. (200×) DETAILED DESCRIPTION
[0093] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0094] The technical scheme in the embodiments of the present invention will be clearly and completely described below in conjunction with the accompanying drawings in the embodiments of the invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in the field without making creative work are within the scope of protection of the present invention. The experimental methods in the following embodiments that do not specify specific conditions are usually based on conventional conditions or according to the conditions recommended by the manufacturer. Unless otherwise stated, all percentages, ratios, proportions or parts are by weight.
[0095] Unless otherwise specified, the reagents and raw materials used in the examples and comparative examples of the present invention can be obtained through commercial channels.
[0096] Example 1
[0097] Step 1, synthesis of Dex-CHO:
[0098] Dextran (Dex) with a molecular weight of 2kDa was dissolved in pure water, ultrasonically dissolved and the air in the solution was removed, and under N2 protection, an oxidant aqueous solution of lead acetate was slowly added, wherein the molar ratio of dextran to oxidant was 1:10, and the reaction was stirred at room temperature for 72h. The reacted solution was poured into an 8-10kD dialysis bag and dialyzed 4 times, 12h / time. After the dialysis, it was dried with a freeze dryer to obtain Dex-CHO with a yield of 72.4%.
[0099] Step 2, synthesis of Dex-CMCS conjugate:
[0100] Dissolve carboxymethyl chitosan (CMCS) with a molecular weight of 2kDa in the solvent DMF, and use ultrasound at room temperature to promote its full dissolution. Remove the air by ultrasound. After cooling, slowly add the above-mentioned DMF solution of Dex-CHO under N2 protection, wherein the molar ratio of carboxymethyl chitosan to Dex-CHO is 0.5:1. Stir the reaction at room temperature for 72 hours, and add the reducing agent lithium aluminum tetrahydride for reduction, wherein the molar ratio of carboxymethyl chitosan to the reducing agent is 1:10. The reaction temperature is 25°C, and the reaction time is 72 hours. Pour the reduced solution into a 8-10kD dialysis bag and dialyze 4 times, 12 hours / time. After the dialysis is completed, dry it with a freeze dryer to obtain Dex-CMCS with a yield of 56.8%;
[0101] Step 3, Synthesis of CMCS-Dex-CHO:
[0102] Take Dex-CMCS and dissolve it in pure water. Ultrasonicate at room temperature to promote its full dissolution, remove air, cool to room temperature, slowly add an aqueous solution of lead acetate as an oxidant under N2 protection, the molar ratio of Dex-CMCS to the oxidant is 1:200, stir at room temperature for 72 hours, pour the solution after the reaction into a 100-500D dialysis bag, dialyze 4 times, 12 hours / time. After the dialysis, dry it with a freeze dryer to obtain CMCS-Dex-CHO with a yield of 68.0%;
[0103] Step 4, synthesis of 6-aminohexanoylferrocene:
[0104] Boc-6-aminocaproic acid was placed in a round-bottom flask, and dry organic solvent tetrahydrofuran was added under ice-salt bath conditions. After complete dissolution, thionyl chloride was added, wherein the molar ratio of Boc-6-aminocaproic acid to thionyl chloride was 0.5:1. The reaction degree was detected by thin layer chromatography. After sufficient reaction for 72 hours, the solvent and excess thionyl chloride were removed. The obtained product did not need further purification, and organic solvent tetrahydrofuran containing ferrocene was directly added, wherein the molar ratio of Boc-6-aminocaproic acid to ferrocene was 0.5:1. Under ice-water bath conditions, the catalyst aluminum chloride was slowly added, wherein the molar ratio of Boc-6-aminocaproic acid to the catalyst was 1:5. The solution was stirred until the color turned purple-red under ice bath conditions. After 72 hours of reaction, pre-cooled pure water was slowly added under ice bath conditions to quench the stratification. The organic layer was spin-dried and redissolved with an organic solvent. Trifluoroacetic acid was added to carry out Boc removal reaction. After the reaction was completed, the solvent was removed and column chromatography (ethyl acetate: petroleum ether = 1:10) was performed to obtain 6-aminohexanoylferrocene with a yield of 42.1%.
[0105] Step 5, Synthesis of Fc-Dex-CMCS conjugate:
[0106] Dissolve CMCS-Dex-CHO in organic solvent DMF, sonicate at room temperature to fully dissolve it, and when it is completely dissolved, slowly add organic solvent DMF containing 6-aminohexanoylferrocene under N2 protection, wherein the molar ratio of CMCS-Dex-CHO to 6-aminohexanoylferrocene is 1:200, stir at room temperature to react for 72 hours, pour the solution after the reaction into a 100-500D dialysis bag, and dialyze 4 times, 12 hours / time. After dialysis, dry it with a freeze dryer to obtain the product Fc-Dex-CMCS (FDC), with a yield of 81.5%.
[0107] Step 6, Synthesis of VDF NPs:
[0108] Take FDC and dissolve it in pure water, ultrasonically dissolve it at room temperature, and after it is completely dissolved, add the organic solvent methanol containing ascorbyl palmitate (VP) and doxorubicin (DOX) slowly to the above solution under ice bath stirring, wherein the molar ratio of FDC to VP is 5:1, and the molar ratio of VP to DOX is 10:1. After stirring and reacting at room temperature for 72 hours, place it on a rotary evaporator to remove the organic solvent, ultrasonically promote particle dispersion, take 2mL and place it in an ultrafiltration centrifuge tube (relative molecular weight cutoff: 3KD), then place it in a 4°C centrifuge, the centrifugal speed is 6000r, the centrifugal time is 30min, and the free VP and DOX in the solution are separated by centrifugation to obtain VDF NPs. The encapsulation efficiency and drug loading are shown in Example 1.
[0109] Example 2
[0110] Step 1, synthesis of Dex-CHO:
[0111] Dextran (Dex) with a molecular weight of 100 kDa was dissolved in pure water, and ultrasonic was used to fully dissolve it and remove the air in the solution. Under the protection of N2, an oxidant sodium periodate aqueous solution was slowly added, wherein the molar ratio of dextran to oxidant was 1:1, and the reaction was stirred at 100°C for 4 hours. The solution after the reaction was poured into a 8-10 kDa dialysis bag and dialyzed 4 times, 12 hours / time. After the dialysis, it was dried with a freeze dryer to obtain Dex-CHO with a yield of 73.4%.
[0112] Step 2, synthesis of Dex-CMCS conjugate:
[0113] Dissolve carboxymethyl chitosan (CMCS) with a molecular weight of 100 kDa in the solvent DMSO, and use ultrasound at 100°C to promote its full dissolution. Remove the air by ultrasound, and after cooling, slowly add the above-mentioned DMSO solution of Dex-CHO under N2 protection, wherein the molar ratio of carboxymethyl chitosan to Dex-CHO is 5:1. Stir the reaction at 100°C for 4 hours, and add the reducing agent sodium borohydride for reduction, wherein the molar ratio of carboxymethyl chitosan to the reducing agent is 1:1. The reaction temperature is 100°C, and the reaction time is 4 hours. Pour the reduced solution into a 8-10 kD dialysis bag and dialyze 4 times, 12 hours / time. After the dialysis, dry it with a freeze dryer to obtain Dex-CMCS with a yield of 53.4%;
[0114] Step 3, Synthesis of CMCS-Dex-CHO:
[0115] Take Dex-CMCS and dissolve it in pure water. Ultrasonicate at 100℃ to promote its full dissolution, remove air, cool to room temperature, slowly add an aqueous solution of oxidant sodium periodate under N2 protection, the molar ratio of Dex-CMCS to oxidant is 1:20, stir at 100℃ for 4h, pour the solution after reaction into a 100-500D dialysis bag, dialyze 4 times, 12h / time. After dialysis, dry it with a freeze dryer to obtain CMCS-Dex-CHO with a yield of 76.3%;
[0116] Step 4, synthesis of 6-aminohexanoylferrocene:
[0117] Boc-6-aminocaproic acid was placed in a round-bottom flask, and dry organic solvent dichloromethane was added under ice-salt bath conditions. After complete dissolution, thionyl chloride was added, wherein the molar ratio of Boc-6-aminocaproic acid to thionyl chloride was 5:1. The reaction degree was detected by thin layer chromatography. After sufficient reaction for 4 hours, the solvent and excess thionyl chloride were removed. The obtained product did not need further purification, and an organic solvent dichloromethane dissolved with ferrocene was directly added, wherein the molar ratio of Boc-6-aminocaproic acid to ferrocene was 5:1. Under ice-water bath conditions, the catalyst zinc chloride was slowly added, wherein the molar ratio of Boc-6-aminocaproic acid to the catalyst was 1:5. The solution was stirred and reacted until the color of the solution turned purple-red under ice bath. After 4 hours of reaction, pre-cooled pure water was slowly added under ice bath to quench the layer. The organic layer was spin-dried and redissolved with an organic solvent. Trifluoroacetic acid was added to carry out Boc removal reaction. After the reaction was completed, the solvent was removed and column chromatography (ethyl acetate: petroleum ether = 1:10) was performed to obtain 6-aminohexanoylferrocene with a yield of 46.1%.
[0118] Step 5, Synthesis of Fc-Dex-CMCS conjugate:
[0119] Dissolve CMCS-Dex-CHO in the organic solvent DMSO, sonicate at 100°C to fully dissolve it, and when it is completely dissolved, slowly add the organic solvent DMSO containing 6-aminohexanoylferrocene under N2 protection, wherein the molar ratio of CMCS-Dex-CHO to 6-aminohexanoylferrocene is 1:20, stir at 100°C for 4 hours, pour the solution after the reaction into a 100-500D dialysis bag, and dialyze 4 times, 12 hours / time. After the dialysis, dry it with a freeze dryer to obtain the product Fc-Dex-CMCS (FDC), with a yield of 84.6%.
[0120] Step 6, Synthesis of VDF NPs:
[0121] FDC was dissolved in pure water and ultrasonically assisted dissolution at 100°C. After complete dissolution, an organic solvent methanol containing ascorbyl palmitate (VP) and doxorubicin (DOX) was slowly added dropwise to the above solution under ice bath stirring, wherein the molar ratio of FDC to VP was 20:1, and the molar ratio of VP to DOX was 50:1. After stirring and reacting at 100°C for 4 hours, the mixture was placed on a rotary evaporator to remove the organic solvent, and ultrasound was used to promote particle dispersion. 2 mL was placed in an ultrafiltration centrifuge tube (relative molecular weight cutoff: 3KD), and then placed in a 4°C centrifuge at a centrifugal speed of 6000r for 30 minutes. The free VP and DOX in the solution were separated by centrifugation to obtain VDF NPs. The encapsulation efficiency and drug loading amount are shown in Example 1.
[0122] Example 3
[0123] Step 1, synthesis of Dex-CHO:
[0124] Dextran (Dex) with a molecular weight of 10kDa was dissolved in pure water, and ultrasonic was used to fully dissolve it and remove the air in the solution. Under the protection of N2, an oxidant aqueous solution of periodic acid was slowly added, wherein the molar ratio of dextran to oxidant was 1:2, and the reaction was stirred at 50°C for 48h. The solution after the reaction was poured into a 8-10kD dialysis bag and dialyzed 4 times, 12h / time. After the dialysis, it was dried with a freeze dryer to obtain Dex-CMCS with a yield of 72.4%.
[0125] Step 2, synthesis of Dex-CMCS conjugate:
[0126] Dissolve carboxymethyl chitosan (CMCS) with a molecular weight of 10 kDa in isopropanol solvent, and ultrasonicate at 50°C to promote its full dissolution. Remove air by ultrasonication. After cooling, slowly add the above-mentioned isopropanol solution of Dex-CHO under N2 protection, wherein the molar ratio of carboxymethyl chitosan to Dex-CHO is 2:1. Stir the reaction at 50°C for 24 hours, and add the reducing agent aluminum isopropoxide for reduction, wherein the molar ratio of carboxymethyl chitosan to the reducing agent is 1:5. The reaction temperature is 60°C, and the reaction time is 48 hours. Pour the reduced solution into a 8-10 kD dialysis bag and dialyze 4 times, 12 hours / time. After the dialysis, dry it with a freeze dryer to obtain Dex-CMCS with a yield of 75.9%;
[0127] Step 3, Synthesis of CMCS-Dex-CHO:
[0128] Take Dex-CMCS and dissolve it in pure water. Ultrasonicate at 50℃ to promote its full dissolution, remove air, cool to room temperature, and slowly add an aqueous solution of oxidant periodic acid under N2 protection. The molar ratio of Dex-CMCS to oxidant is 1:50. Stir and react at 50℃ for 48h. Pour the solution after the reaction into a 100-500D dialysis bag and dialyze 4 times, 12h / time. After the dialysis, dry it with a freeze dryer to obtain CMCS-Dex-CHO with a yield of 80.2%;
[0129] Step 4, synthesis of 6-aminohexanoylferrocene:
[0130] Boc-6-aminocaproic acid was placed in a round-bottom flask, and dry organic solvent carbon disulfide was added under ice-salt bath conditions. After complete dissolution, thionyl chloride was added, wherein the molar ratio of Boc-6-aminocaproic acid to thionyl chloride was 2:1. The reaction degree was detected by thin layer chromatography. After sufficient reaction for 48 hours, the solvent and excess thionyl chloride were removed. The obtained product did not need to be further purified, and organic solvent carbon disulfide dissolved with ferrocene was directly added, wherein the molar ratio of Boc-6-aminocaproic acid to ferrocene was 2:1. Under ice-water bath conditions, catalyst ferric chloride was slowly added until the color of the solution changed to purple-red. Under ice bath conditions, stirring and reaction were continued. After the reaction for 48 hours, pre-cooled pure water was slowly added under ice bath conditions, and the layers were quenched and separated. After the organic layer was spin-dried, it was redissolved with an organic solvent, and trifluoroacetic acid was added to carry out a Boc removal reaction. After the reaction was completed, the solvent was removed, and column chromatography (ethyl acetate: petroleum ether = 1:10) was performed to obtain 6-aminocaproylferrocene, and the yield was 54.6%;
[0131] Step 5, Synthesis of Fc-Dex-CMCS conjugate:
[0132] Dissolve CMCS-Dex-CHO in acetonitrile, an organic solvent, and dissolve it completely by ultrasonic treatment at 50°C. After the solution is completely dissolved, slowly add acetonitrile, an organic solvent, containing 6-aminohexanoylferrocene, under the protection of N2, wherein the molar ratio of CMCS-Dex-CHO to 6-aminohexanoylferrocene is 1:50, stir at 50°C for 48 hours, pour the solution after the reaction into a 100-500D dialysis bag, and dialyze 4 times, 12 hours / time. After the dialysis, dry it with a freeze dryer to obtain the product Fc-Dex-CMCS (FDC), with a yield of 85.2%.
[0133] Step 6, Synthesis of VDF NPs:
[0134] FDC was dissolved in pure water and ultrasonically assisted dissolution at 50°C. After complete dissolution, an organic solvent ethanol containing ascorbyl palmitate (VP) and doxorubicin (DOX) was slowly added dropwise to the above solution under ice bath stirring, wherein the molar ratio of FDC to VP was 10:1, and the molar ratio of VP to DOX was 20:1. After stirring at 50°C for 48 hours, the mixture was placed on a rotary evaporator to remove the organic solvent, and ultrasound was used to promote particle dispersion. 2 mL was placed in an ultrafiltration centrifuge tube (relative molecular weight cutoff: 3KD), and then placed in a 4°C centrifuge at a centrifugal speed of 6000r for 30 minutes. The free VP and DOX in the solution were separated by centrifugation to obtain VDF NPs. The encapsulation efficiency and drug loading were shown in Example 1.
[0135] Example 4
[0136] Step 1, synthesis of Dex-CHO:
[0137] Dextran (Dex) with a molecular weight of 20 kDa was dissolved in pure water, and ultrasonic was used to fully dissolve it and remove the air in the solution. Under the protection of N2, an oxidant aqueous solution of periodic acid was slowly added, wherein the molar ratio of dextran to oxidant was 1:5, and the reaction was stirred at 80°C for 24 hours. The solution after the reaction was poured into a 8-10 kDa dialysis bag and dialyzed 4 times, 12 hours / time. After the dialysis, it was dried with a freeze dryer to obtain Dex-CMCS with a yield of 83.6%.
[0138] Step 2, synthesis of Dex-CMCS conjugate:
[0139] Dissolve carboxymethyl chitosan (CMCS) with a molecular weight of 20 kDa in solvent DMF, and use ultrasound at 80°C to promote its full dissolution. Remove air by ultrasound, and after cooling, slowly add the above-mentioned DMF solution of Dex-CHO under N2 protection, wherein the molar ratio of carboxymethyl chitosan to Dex-CHO is 3:1. Stir the reaction at 80°C for 24 hours, and add the reducing agent aluminum isopropoxide for reduction, wherein the molar ratio of carboxymethyl chitosan to the reducing agent is 1:8. The reaction temperature is 80°C, and the reaction time is 24 hours. Pour the reduced solution into a 8-10 kD dialysis bag and dialyze 4 times, 12 hours / time. After the dialysis, dry it with a freeze dryer to obtain Dex-CMCS with a yield of 89.1%;
[0140] Step 3, Synthesis of CMCS-Dex-CHO:
[0141] Take Dex-CMCS and dissolve it in pure water. Ultrasonicate at 80℃ to promote its full dissolution, remove air, cool to room temperature, and slowly add an aqueous solution of oxidant periodic acid under N2 protection. The molar ratio of Dex-CMCS to oxidant is 1:100. Stir and react at 80℃ for 24h. Pour the solution after the reaction into a 100-500D dialysis bag and dialyze 4 times, 12h / time. After the dialysis, dry it with a freeze dryer to obtain CMCS-Dex-CHO with a yield of 82.7%;
[0142] Step 4, synthesis of 6-aminohexanoylferrocene:
[0143] Boc-6-aminocaproic acid was placed in a round-bottom flask, and dry organic solvent dichloromethane was added under ice-salt bath conditions. After complete dissolution, thionyl chloride was added, wherein the molar ratio of Boc-6-aminocaproic acid to thionyl chloride was 3:1. The reaction degree was detected by thin layer chromatography. After sufficient reaction for 36 hours, the solvent and excess thionyl chloride were removed. The obtained product did not need to be further purified, and dichloromethane containing ferrocene was directly added, wherein the molar ratio of Boc-6-aminocaproic acid to ferrocene was 3:1. Under ice-water bath conditions, the catalyst ferric chloride was slowly added until the color of the solution changed to purple-red. Under ice bath conditions, the reaction was continued with stirring. After the reaction for 36 hours, pure water precooled in advance was slowly added under ice bath conditions to quench the layer. After the organic layer was spin-dried, it was redissolved in an organic solvent, and trifluoroacetic acid was added to carry out a Boc removal reaction. After the reaction was completed, the solvent was removed, and column chromatography (ethyl acetate: petroleum ether = 1:10) was performed to obtain 6-aminocaproylferrocene, with a yield of 60.3%;
[0144] Step 5, Synthesis of Fc-Dex-CMCS conjugate:
[0145] Dissolve CMCS-Dex-CHO in the organic solvent DMSO, and fully dissolve it by ultrasonication at 80°C. After it is completely dissolved, slowly add the organic solvent DMSO containing 6-aminohexanoylferrocene under N2 protection, wherein the molar ratio of CMCS-Dex-CHO to 6-aminohexanoylferrocene is 1:100, stir and react at 80°C for 24 hours, pour the solution after the reaction into a 100-500D dialysis bag, and dialyze 4 times, 12 hours / time. After the dialysis is completed, dry it with a freeze dryer to obtain the product Fc-Dex-CMCS (FDC), with a yield of 89.4%.
[0146] Step 6, Synthesis of VDF NPs:
[0147] FDC was dissolved in pure water and ultrasonically assisted dissolution at 80°C. After complete dissolution, an organic solvent ethanol containing ascorbyl palmitate (VP) and doxorubicin (DOX) was slowly added dropwise to the above solution under ice bath stirring, wherein the molar ratio of FDC to VP was 15:1, and the molar ratio of VP to DOX was 30:1. After stirring and reacting at 80°C for 24 hours, the mixture was placed on a rotary evaporator to remove the organic solvent, and ultrasound was used to promote particle dispersion. 2 mL was placed in an ultrafiltration centrifuge tube (relative molecular weight cutoff: 3KD), and then placed in a 4°C centrifuge at a centrifugal speed of 6000r for 30 minutes. The free VP and DOX in the solution were separated by centrifugation to obtain VDF NPs. The encapsulation efficiency and drug loading were shown in Example 1.
[0148] Example 5
[0149] Step 1, synthesis of Dex-CHO:
[0150] Dextran (Dex) with a molecular weight of 50 kDa was dissolved in pure water, and ultrasonic was used to fully dissolve it and remove the air in the solution. Under the protection of N2, an oxidant sodium periodate aqueous solution was slowly added, wherein the molar ratio of dextran to oxidant was 1:8, and the reaction was stirred at 60°C for 48 hours. The solution after the reaction was poured into a 8-10 kDa dialysis bag and dialyzed 4 times, 12 hours / time. After the dialysis, it was dried with a freeze dryer to obtain Dex-CMCS with a yield of 78.7%.
[0151] Step 2, synthesis of Dex-CMCS conjugate:
[0152] Dissolve carboxymethyl chitosan (CMCS) with a molecular weight of 50 kDa in the solvent DMSO, and use ultrasound at 60°C to promote its full dissolution. Remove the air by ultrasound, and after cooling, slowly add the above-mentioned DMSO solution of Dex-CHO under N2 protection, wherein the molar ratio of carboxymethyl chitosan to Dex-CHO is 4:1. Stir the reaction at 60°C for 24 hours, and add the reducing agent aluminum isopropoxide for reduction, wherein the molar ratio of carboxymethyl chitosan to the reducing agent is 1:8. The reaction temperature is 80°C, and the reaction time is 24 hours. Pour the reduced solution into a 8-10 kD dialysis bag and dialyze 4 times, 12 hours / time. After the dialysis, dry it with a freeze dryer to obtain Dex-CMCS with a yield of 78.0%;
[0153] Step 3, Synthesis of CMCS-Dex-CHO:
[0154] Take Dex-CMCS and dissolve it in pure water, sonicate at 60℃ to promote its full dissolution, remove air, cool to room temperature, slowly add aqueous solution of oxidant sodium periodate under N2 protection, the molar ratio of Dex-CMCS to oxidant is 1:150, stir and react at 60℃ for 36h, pour the solution after reaction into 100-500D dialysis bag, dialyze 4 times, 12h / time. After dialysis, dry it with freeze dryer to obtain CMCS-Dex-CHO, with a yield of 85.3%;
[0155] Step 4, synthesis of 6-aminohexanoylferrocene:
[0156] Boc-6-aminocaproic acid was placed in a round-bottom flask, and dry organic solvent tetrahydrofuran was added under ice-salt bath conditions. After complete dissolution, thionyl chloride was added, wherein the molar ratio of Boc-6-aminocaproic acid to thionyl chloride was 4:1. The reaction degree was detected by thin layer chromatography. After sufficient reaction for 8 hours, the solvent and excess thionyl chloride were removed. The obtained product did not need to be further purified, and organic solvent tetrahydrofuran containing ferrocene was directly added, wherein the molar ratio of Boc-6-aminocaproic acid to ferrocene was 4:1. Under ice-water bath conditions, catalyst titanium tetrachloride was slowly added until the color of the solution changed to purple-red. Under ice bath conditions, stirring and reaction were continued. After the reaction for 6 hours, pre-cooled pure water was slowly added under ice bath conditions, and the layers were quenched and separated. After the organic layer was spin-dried, it was redissolved with an organic solvent, and trifluoroacetic acid was added to carry out a Boc removal reaction. After the reaction was completed, the solvent was removed, and column chromatography (ethyl acetate: petroleum ether = 1:10) was performed to obtain 6-aminocaproylferrocene, and the yield was 52.7%;
[0157] Step 5, Synthesis of Fc-Dex-CMCS conjugate:
[0158] Dissolve CMCS-Dex-CHO in organic solvent DMF, sonicate at 60℃ to fully dissolve it, and slowly add organic solvent DMF containing 6-aminohexanoylferrocene under N2 protection, wherein the molar ratio of CMCS-Dex-CHO to 6-aminohexanoylferrocene is 1:150, stir at 60℃ for 6h, pour the solution after reaction into 100-500D dialysis bag, and dialyze 4 times, 12h / time. After dialysis, dry it with freeze dryer to obtain product Fc-Dex-CMCS (FDC), with a yield of 71.3%.
[0159] Step 6, Synthesis of VDF NPs:
[0160] FDC was dissolved in pure water and ultrasonically assisted dissolution at 60°C. After complete dissolution, an organic solvent ethanol containing ascorbyl palmitate (VP) and doxorubicin (DOX) was slowly added dropwise to the above solution under stirring in an ice bath, wherein the molar ratio of FDC to VP was 10:1, and the molar ratio of VP to DOX was 40:1. After stirring and reacting at 60°C for 8 hours, the mixture was placed on a rotary evaporator to remove the organic solvent, and ultrasonically promoted particle dispersion. 2 mL was placed in an ultrafiltration centrifuge tube (relative molecular weight cutoff: 3KD), and then placed in a 4°C centrifuge at a centrifugal speed of 6000r for 30 minutes. The free VP and DOX in the solution were separated by centrifugation to obtain VDF NPs. The encapsulation efficiency and drug loading were shown in Example 1.
[0161] Effect Example 1
[0162] The amphiphilic functional nanocomplexes obtained in Examples 1 to 5 were used to perform the following evaluations on Pan02 pancreatic cancer cells and mice inoculated with pancreatic cancer:
[0163] Characterization of Dex, Dex-CHO, CMCS, CMCS-Dex and CMCS-Dex-CHO: The aldehyde proton hydrogen of Dex-CHO and CMCS-Dex-CHO appeared at 8.46 ppm ( Figure 1 A), the amino proton hydrogen of CMCS appeared at 2.06ppm in the CMCS-Dex spectrum, while the proton hydrogen signal corresponding to the aldehyde group of Dex-CHO disappeared; at the same time, FT-IR ( Figure 1 B) Further identification, Dex-CHO and CMCS-Dex-CHO were 1740 cm -1 At 1720cm -1 The characteristic peaks of aldehyde stretching vibration appeared at , confirming the successful preparation of each step of the product. Complete 1H NMR characterization of CMCS-Dex-CHO: 1H NMR (500MHz, D2O) δ8.46 (s, 1H), 5.71 (s, 2H), 5.56 (d, J = 11.2Hz, 1H), 5.48-5.40 (m, 1H), 5.35 (d, J = 5.1Hz, 1H), 5.20 (s, 3H), 5.14-5.06 (m, 2H), 5.04-4.94 (m, 5H), 4.90 (s, 1H), 4. 73(s,1H),4.61(s,1H),4.33(d,J=13.4Hz,3H),4.15(s,2H),4.04-3.95(m,7H),3.91(s,1 1H), 3.75 (dd, J=19.8, 10.2Hz, 12H), 3.60 (s, 4H), 3.56 (s, 2H), 3.54 (s, 2H), 2.06 (s, 1H).
[0164] Characterization of Fc Figure 2 ): Figure 2 As shown in A, 1H NMR (500MHz, CDCl3) δ4.77(s,1H),4.49(s,1H),4.19(s,2H),3.13(s,1H),2.70(t,J=7. 4Hz,1H),1.72(p,J=7.4Hz,1H),1.53(dt,J=14.6,6.8Hz,1H),1.44(s,5H),0.06(s,1H). Figure 2 As shown in B, MS (ESI) m / z, Calcd for C16H21FeNO (M) + 299.00, found 300.61 (M+H) +.
[0165] Characterization of Fc-Dex-CMCS conjugates: The chemical structure was determined using 1H-NMR and FT-IR ( Figure 3 ). Figure 3 As shown in A, the carbonyl proton hydrogen of Fc-Dex-CMCS appears at 6.61ppm, and the aldehyde proton hydrogen at 8.10ppm almost disappears, indicating the successful coupling of CMCS-Dex-CHO with Fc. Specific nuclear magnetic characterization: 1H NMR (500MHz, DMSO-d6) δ8.10 (s, 1H), 6.79–6.42 (m, 8H), 5.38 (s, 4H), 5.03 (s, 4H), 4.75 (s, 8H), 4.51 (s, 2H), 4.18 (s, 4H), 3.99 (d, J=7.1Hz, 4H), 3.91 (s, 2H), 3.71 (s, 6H), 3.57 (s,7H),2.95(s,1H),2.92(s,1H),2.89(s,2H),2.64(s,3H),2.36(s,3H),2.32(s,1H), 2.25(s,2H),1.95(s,4H),1.33(s,6H),1.19(s,2H),1.13(t,J=7.1Hz,4H),0.81(s,1H); Figure 3 As shown in B, FT-IR was further used to verify that the stretching signal at 3000 cm-1 and the strong stretching signal at 1100-1000 cm-1 were due to the vibration of the imine bond in Fc-Dex-CMCS, confirming the successful preparation of Fc-Dex-CMCS.
[0166] Characterization of VDF NPs: Figure 4 As shown in A, the morphological structure of VDF NPs was photographed using TEM. Under the electron microscope, VDF NPs were evenly distributed and the morphological structure was round or elliptical, which was consistent with the structural morphology of nanoparticles. Figure 4As shown in B, the particle size of VDF NPs detected by a particle size potentiometer is 128.80±4.50nm, the PDI is 0.192±0.025, and the Zeta is -50.94±3.05. The larger charge indicates that the nanoparticles may have better stability. Figure 4 C shows the Zeta potential diagram of VDF NPs under different pH conditions. When the pH is 7.4, the Zeta potential of VDF NPs is -50.94 mV. When the pH is 5.5, the charge changes from negative to positive (11.74 mV), indicating that the nanomedicine has a charge reversal property. The schematic diagram is shown in Figure 4 D. The observed pH-dependent potential changes were attributed to the hydrophilic side chain carboxymethyl chitosan. After screening the optimal feed ratio, the encapsulation efficiencies of VP and DOX were (89.93±5.15)% and (78.92±5.98)%, and the drug loadings of VP and DOX were (8.05±0.45)% and (0.43±0.01)%, respectively.
[0167]
[0168] Effect Example 2
[0169] The following are the in vitro stability, in vitro release analysis, and in vitro efficacy experiments of the VDF NPs obtained in Examples 1-5:
[0170] In vitro stability of VDF NPs: The stability of VDF NPs at 4°C and 37°C was tested using a particle size potential analyzer. At 4°C, the particle size of VDF NPs slightly increased in the first 5 days and then remained basically unchanged ( Figure 6 A), PDI remains around 0.200 ( Figure 6 B), the Zeta potential dropped slightly on the second day, and then remained basically unchanged, always remaining around -50mV ( Figure 6 C), indicating that the nanoparticles have good stability under 4°C storage conditions. To simulate the in vivo environment, VDF NPs were added to PBS, fetal bovine serum, and DMEM containing 10% fetal bovine serum, respectively, and stored in a shaker at 37°C and 100 rpm / min. The results showed that ( Figure 6 DF), in PBS, the particle size and PDI are slightly larger than those in deionized water, while the Zeta potential is decreased, which may be affected by the ions in the PBS buffer, but it still remains in a relatively stable state; in fetal bovine serum and DMEM containing 10% fetal bovine serum, the PDI is increased compared with that in deionized water, and the particle size and Zeta potential are lower than those in deionized water, which may be affected by some proteins, but the surface charge is still negative and relatively stable.
[0171] In vitro release analysis of VDF NPs: The in vitro release of VP and DOX from VDF NPs in PBS (pH = 7.4 and 5.5) was determined by dialysis at 37°C. Figure 7 As shown in A, under pH = 7.4, the release of VP after 24 hours was about 63.74%; when pH was 5.5, the release rate of VP was significantly accelerated, and the cumulative release reached 81.66% within 12 hours. Figure 7 B) Similar to VP, within 48 h, the release rate and cumulative release amount of DOX from VDF NPs at pH 5.5 were higher than those at pH 7.4 (2-13(B)). The above results show that the release of VDF NPs is acidic and time-dependent.
[0172] In vitro efficacy experiment: Pan02 cells were seeded in a 96-well plate at a density of 1×104 cells / well, with 6 replicates per group, 100 μL culture medium / well, PBS was added to each plate for four weeks, and cultured in a 5% CO2, 37°C incubator for 24 hours. The cells were observed under a microscope, and after confirming that the cells were in good condition, the old culture medium was discarded, washed twice with PBS, and the drug-containing culture medium was added according to the concentration shown in Table 3-4 and continued to be cultured for 24 hours (VP / DOX / FDC Mix and VDF NPs concentrations were expressed as DOX). After the incubation, the cell activity was detected using a CCK-8 kit.
[0173] To evaluate the synergistic effect between VP and DOX, we detected the activity of VP@FDC NPs ( Figure 8 A), DOX@FDC NPs( Figure 8 B) and VDF NPs( Figure 8 C) Effect on the viability of Pan02 cells. Figure 8 As shown in the figure, the IC50 values of VP@FDCNPs, DOX@FDC NPs and VDF NPs were 30.06±2.57μg / mL, 0.992±0.207μg / mL and 0.135±0.022μg / mL, respectively, and the combination index (CI) was 0.226±0.066<1. The IC50 value of co-loaded nanoparticles was significantly lower than that of single drug nanoparticles, and the CI value was much less than 1, indicating that VP and DOX have a strong synergistic effect and can significantly enhance their anticancer effects.
[0174] In order to understand the effects of VP, DOX, FDC, VP / DOX / FDC Mix and VDF NPs on the viability of Pan02 cells, the CCK-8 method was used to detect the survival rate of cells after 24 h of drug treatment. Fig. 9As shown. FDC has a low effect on the viability of Pan02 cells, indicating that the carrier material has low toxicity and good biocompatibility. VP, DOX, VP / DOX / FDC Mix and VDF NPs all showed a certain inhibitory effect as the concentration of administration gradually increased, among which VDF NPs had a stronger inhibitory effect than VP / DOX / FDC Mix at the same concentration (**P<0.01). This result shows that nanomedicines prepared can exert a stronger anti-cancer effect than simple physical mixing.
[0175] Intracellular H2O2 concentration detection: Pan02 cells were seeded in a 60 mm culture dish at a cell density of 1×106 cells / dish, and the cells were completely attached to the wall. The old culture medium was discarded, and 5 mL of VP (2 μg / mL), DOX (100 ng / mL) and FDC (20 μg / mL) were added respectively. 5.0 mL of the culture medium was added to the blank control group. After incubation in a cell culture incubator for 24 hours, the culture medium was discarded, and the cells were washed three times with 1 mL of PBS, counted, and collected by centrifugation. According to the formula of 1×10 6 The lysate was added at a ratio of 1 cell to 200 μL of cell lysate. After the cells were fully homogenized and lysed, they were centrifuged at 15,000 rpm / min at 4°C for 5 minutes, and the supernatant was collected. Finally, a standard curve was prepared according to the operating requirements of the hydrogen peroxide detection kit to determine the concentration of H2O2 in the sample.
[0176] After VP and DOX act on Pan02 cells, they can activate the reduced nicotinamide adenine dinucleotide phosphate oxidase (NOXs) in the cells to reduce O2 molecules to singlet oxygen (O2·-). The half-life of O2·- in cells is very short (10 - 6 s), and O2·- can be quickly transferred to H2O2 through superoxide dismutase (SOD). The rapidly increasing H2O2 can be converted into highly toxic ·OH through the Fenton reaction catalyzed by ferrocene coupled to the carrier, thereby killing tumor cells ( Fig.10 A) The relative content of H2O2 in cells of different groups Fig.10 As shown in B, both the VP group and the DOX group increased the concentration of H2O2 in Pan02 cells (**P<0.01), while the H2O2 content in the FDC group was lower than that in the normal control group (*P<0.05). In summary, VP and DOX can produce H2O2 in cells, and the produced H2O2 can generate highly toxic ·OH through the Fenton reaction catalyzed by the carrier.
[0177] In vivo pharmacodynamics experiment: Pan02 cells were cultured and the cells were grown in logarithmic phase. The cells were digested with trypsin and digested with serum. The supernatant was removed after low-speed centrifugation and 1×107 The mouse tumor model was constructed by subcutaneously injecting 100 μL of cell suspension into the right armpit of the mouse. The living conditions of the mice were observed daily after inoculation. The tumor growth rate of each group of mice was observed after one week. The model was successfully established when a nodule was touched at the inoculation site. The long and short diameters of the tumor were measured with an electronic vernier caliper, and the tumor volume was calculated according to the formula. Tumor volume (mm 3 ) = long diameter (mm) × short diameter 2 (mm 2 )×1 / 2
[0178] The tumor in the tumor-bearing mice grew to about 80 mm 3 At 14:00, the mice were randomly divided into 9 groups (ensuring that the tumor volume of each group of mice was equal during grouping), namely normal group (Control), model group (Model), VP, DOX, FDC, VP / DOX / FDC Mix and VDF NPs low, medium and high dose groups, with 6 mice in each group. According to VP (8 mg / Kg), DOX (0.4 mg / Kg), FDC (80 mg / Kg), VP / DOX / FDC Mix (the content of each component is the same as above) and VDF NPs low, medium and high dose groups (where the DOX content is 0.4, 0.6, 0.8 mg / kg), the tail vein injection was administered, and the saline was prepared with a volume of 0.1 mL / 10 g. The tail vein injection was administered once every other day for 7 consecutive times. The control group and the model group were injected with the same volume of saline. During the administration period, the survival and growth of the mice were observed every day, and the weight of the mice was weighed and the tumor volume was measured on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 14th day, respectively. After 7 doses of medication, the eyeballs were removed to collect blood, and the blood was dripped into a 1.5 mL centrifuge tube, and 200 μL of the blood was immediately added to an EDTA-k2 anticoagulant tube. After the mice were killed, the tumors were removed, photographed, and weighed, and the tumor growth inhibition rate (TGI) was calculated. TGI = (1-(tumor mass of the treatment group) / (average tumor mass of the saline group)) × 100%
[0179] Part of the tumor was frozen in liquid nitrogen. The liver, heart, spleen, lung and kidney of the mouse were removed, washed with saline to remove the blood stains on the surface, and then fixed in 4% paraformaldehyde.
[0180] HE staining operation steps: Tumor, heart, liver, spleen, lung and kidney tissues fixed with 4% paraformaldehyde for more than 24 hours were removed, embedded in paraffin, sliced, and stained with H&E. The slices were scanned using a pathological slice scanner and analyzed using K-viewer 1.51 software. The specific operation steps are as follows: (1) Paraffin section: Dewax and hydrate according to the conventional method, and soak the sections in xylene twice, each time for 15 minutes → soak in anhydrous ethanol twice, each time for 5 minutes → 80% ethanol for 5 minutes → wash with distilled water for 5 minutes; (2) Hematoxylin staining: stain with hematoxylin solution for 5-10 minutes → wash with water for 10 minutes or rinse with running water for 5 minutes → differentiate with 1% hydrochloric acid ethanol differentiation solution for 30 seconds → wash with water for 10 seconds → blueing with blueing solution → rinse with running water; (3) Eosin staining: stain with 0.5% eosin solution for 1-3 minutes → wash with water for 30 seconds → dehydrate with 80% and 95% ethanol for 3 minutes each; (4) Dehydration and sealing: soak the sections in anhydrous ethanol twice, each time for 5 minutes → soak in xylene twice, each time for 5 minutes → seal with neutral gum.
[0181] Pan02 pancreatic cancer cells were inoculated in the right armpit of mice to create a tumor model. After the drug administration, the tumor was obtained and analyzed. During the treatment, except for the high-dose VDF NPs group, the weight of mice in other groups did not change significantly. This is the result of the dual effects of drug toxicity and tumor progression on mice during the administration period ( Fig.11 A). Each drug-treated group inhibited tumor growth to varying degrees ( Fig.11 B), the difference between each drug administration group and the model group was calculated by the tumor volume on the last day. The results showed that except for the FDC group, there were significant differences between the other drug administration groups and the model group (**P<0.01, ***P<0.01); the difference between the VP / DOX / FDC Mix group, the VDF NPs low, medium, high groups and the VP group was calculated by the tumor volume on the last day, indicating that the VP / DOX / FDC Mix group and the VDF NPs low, medium, high dose groups were significantly different from the VP group (##P<0.01, ###P<0.001); the difference between the VP / DOX / FDC Mix group, the VDF NPs low, medium, high dose groups and the DOX group was calculated by the tumor volume on the last day, indicating that the VDF NPs low, medium, high dose groups were significantly different from the DOX group (△△P<0.01, △△△P<0.001), while there was no significant difference between the VP / DOX / FDC Mix group and the DOX group. The removed tumors were weighed ( Fig.11 C), calculate the tumor inhibition rate ( Fig.11 D) and took photos of the excised tumor ( Fig.11E), the tumor growth inhibition rates of the VP / DOX / FDC Mix group and the VDFNPs low, medium, and high dose groups were 39.64±6.92%, 45.32±6.63%, 51.40±4.28%, and 60.56±4.30%, respectively, which were significantly different from the VP group tumor inhibition rate of 26.32±9.34% (*P<0.05, **P<0.01, ***P<0.001); the VDF NPs low, medium, and high dose groups were significantly different from the DOX group tumor inhibition rate of 31.51±4.87% (##P<0.01, ###P<0.001), while there was no significant difference between the VP / DOX / FDC Mix group and the DOX group. In order to further evaluate the antitumor activity of each drug administration group, HE staining was used to detect the morphological changes of tumor tissue ( Fig.11 F), the results showed that each drug administration group had a certain anti-tumor activity. In summary, under the same concentration conditions, the VDF NPs group can exert a stronger anti-tumor effect than the original drug group and the VP / DOX / FDC Mix group, which may be attributed to the higher negative charge on the carrier surface after intravenous injection, which can prolong the circulation time of the drug and provide more opportunities to reach the tumor site through the EPR effect.
[0182] In vivo safety analysis: (1) Routine blood analysis: 200 μL of mouse blood was added to an EDTA-k2 anticoagulant tube, and the content of red blood cells (RBC), white blood cells (WBC), hemoglobin (HGB) and platelets (PLT) was detected using a fully automatic blood cell analyzer. (2) Blood biochemical test: The mouse eyeball was removed and blood was collected in a centrifuge tube. After standing in a 4°C centrifuge for 1 hour, it was centrifuged at 3500 rpm / min for 15 minutes. The upper serum was taken and the liver and kidney function indicators were detected using a kit. Liver function indicators: alanine aminotransferase (ALT) and aspartate aminotransferase (AST), renal function kit blood urea (BUN) and creatinine (CR), according to the operating procedures in the kit test instructions, the effects of each group of drugs on the liver and kidney function of mice were evaluated in turn. (3) The HE tissue staining operation steps are shown in Part 9.
[0183] The results of HE staining of tissues showed that ( Fig.12 ), the histological morphology of the heart, liver, spleen, lung and kidney tissues of each group of mice showed normal, and no substantial pathological changes were found in each organ.
[0184] In order to further explore the toxic effects of each drug-administered group on the blood system, blood routine tests were performed ( Fig.13), and the items with large differences were selected for bar graph analysis. When the blood system of mice is poisoned, the content of white blood cells (WBC) in the blood tends to increase, and the levels of red blood cells (RBC), hemoglobin (HGB) and platelets (PLT) decrease. The results showed that the effects of each drug administration group on the content of red blood cells and hemoglobin were not significant, and the main effects were on the content of white blood cells and platelets. The results showed that DOX had a greater effect on both white blood cells and platelets, but with the addition of VP and the increase in concentration, the number of white blood cells and platelets in the blood of the physical mixing group and the low, medium and high dose groups of nanomedicines tended to be normal after 14 days of administration. The results show that the toxicity of VDF NPs to the blood system is not obvious, and the addition of VP weakens the blood toxicity of DOX to a certain extent.
[0185] Blood biochemistry mainly tests liver function and kidney function ( Fig.14 ), and its detection indicators were aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine (CRE) and urea nitrogen (BUN). If the above four indicators are higher than normal values, it means that the function of the liver and kidney is impaired. The results showed that compared with the Control group, the ALT, CRE and BUN levels in the DOX group were significantly increased (P<0.01), and the CRE content in the high-dose VDF NPs group was significantly increased (P<0.05). In addition, there were no significant changes in the liver and kidney indicators of the VP, FDC, VP / DOX / FDC Mix and VDFNPs low, medium and high dose groups. The above results show that DOX has certain toxicity to the liver and kidneys, and the combined use of VP can weaken the toxic effects of DOX on the liver and kidneys.
[0186] Tumor immunohistochemical analysis: The tissue was cut into 5 μm sections and the expression of Ki67 in the tumor was detected by immunohistochemical staining. Brown staining of the cytoplasm or nucleus indicated a positive result. The specific steps are as follows:
[0187] (1) Antigen repair: After the paraffin sections are dewaxed and hydrated, they are placed in an EDTA (pH 9.0) repair box in a microwave oven for antigen repair. Heat on medium heat for 8 minutes until boiling, then turn off the heat for 8 minutes to keep warm and then turn to medium heat for 7 minutes. After natural cooling, the slides are placed in PBS (pH 7.4) and washed by shaking on a decolorizing shaker;
[0188] (2) Blocking endogenous peroxidase: Place the sections in a 3% H202 aqueous solution and incubate at room temperature in the dark for 25 min. Place the slides in PBS (pH 7.4) and wash them three times on a decolorizing shaker for 5 min each time.
[0189] (3) Serum blocking: Add 3% BSA in the tissue circle to evenly cover the tissue and block at room temperature for 30 minutes. (If the primary antibody is from goat, use rabbit serum to block; if it is from other sources, use BSA to block);
[0190] (4) Add primary antibody: Gently shake off the blocking solution, add primary antibody diluted with PBS at a ratio of 1:200 to 1:500 to the sliced tissue, place the slice flat in a moisturizing box, and incubate at 4°C overnight. (Add a small amount of water to the moist box to prevent evaporation of the antibody solution);
[0191] (5) Adding secondary antibody: Place the slide in PBS (pH 7.4) and wash on a decolorizing shaker three times, 5 min each time. After the slices are slightly dried, add the secondary antibody (HRP-labeled) of the same species as the primary antibody to cover the tissue and incubate at room temperature for 50 min.
[0192] (6) DAB color development: Place the slide in PBS (pH 7.4) and wash it on a decolorizing shaker three times, each wash for 5 min. After the slices are slightly dried, add freshly prepared DAB color development solution in the circle. The color development time is controlled under a microscope. The positive color is brown-yellow. Rinse the slices with tap water to stop the color development.
[0193] (7) Counterstaining of cell nuclei: Soak tissue sections in hematoxylin for counterstaining for about 1 min, wash off the surface dye with tap water, place in hematoxylin differentiation solution for a few seconds, wash with water, place in hematoxylin bluing solution for bluing, and rinse with running water;
[0194] (8) Dehydration and sealing: Place the tissue sections in 75% ethanol for 5 min, 85% ethanol for 5 min, anhydrous ethanol twice, 5 min each time, and xylene for 5 min to dehydrate and make them transparent. Take the tissue sections out of xylene and let them dry slightly, then seal them with neutral gum.
[0195] (9) Photography: The sealed sections were observed under a microscope and images were collected. The nuclei stained with hematoxylin were blue, and the positive expression shown by DAB was brown-yellow.
[0196] Ki67 protein is a commonly used indicator in pathological diagnosis. The more Ki67 protein is expressed, the faster the cell proliferation is, and vice versa. Fig.15 As shown in the figure, the positive expression of Ki67 is shown as brown nuclei. In the Model group, Ki67 protein is expressed in large quantities, while the expression of Ki67 protein in the VP group, DOX group, VP / DOX / FDC Mix group and VDF NPs low, medium and high dose groups is significantly reduced. Among them, the expression of Ki67 protein in the tumor sections of the group treated with VDF NPs is the lowest. The above results indicate that VDF NPs can inhibit tumor growth by inhibiting tumor cell proliferation.
[0197] Glutathione peroxidase 4 (GPX4) fluorescence assay
[0198] (1) Dewaxing of paraffin sections: Place the sections in environmentally friendly dewaxing solution I for 10 min → environmentally friendly dewaxing solution II for 10 min → environmentally friendly dewaxing solution III for 10 min → anhydrous ethanol I for 5 min → anhydrous ethanol II for 5 min → anhydrous ethanol III for 5 min → wash with distilled water.
[0199] (2) Antigen repair: After boiling the citric acid repair solution (pH 6.0) under high pressure, place it on a slice rack and cover it tightly until it sprays air for 2 minutes. Stop heating, rinse with tap water until it cools down, open the cover and take it out. Place the slide in PBS (pH 7.4) and shake it on a decolorizing shaker to wash it 3 times, each time for 5 minutes.
[0200] (3) Circle serum blocking: After the slices are slightly dried, use a histochemical pen to draw a circle around the tissue, add BSA (if the primary antibody is from goat, use 10% donkey serum to block; if the primary antibody is from other sources, use 3% BSA to block), and block for 30 minutes.
[0201] (4) Add primary antibody: Add the prepared primary antibody dropwise and incubate the sections flat in a humidified chamber at 4°C overnight.
[0202] (5) Adding secondary antibody: Place the slide in PBS (pH 7.4) and wash on a decolorizing shaker three times, 5 min each time. Add the corresponding secondary antibody and incubate at room temperature in the dark for 50 min.
[0203] (6) DAPI counterstaining of cell nuclei: Place the slide in PBS (pH 7.4) and wash on a decolorizing shaker three times, 5 min each time. Add DAPI staining solution and incubate at room temperature for 10 min in the dark.
[0204] (7) Quenching tissue autofluorescence: Place the slide in PBS (pH 7.4) and wash on a decolorizing shaker three times, 5 min each time. Add autofluorescence quencher B solution for 5 min and rinse with running water for 10 min.
[0205] (8) Sealing: Use anti-fluorescence quenching sealing medium to seal the slices.
[0206] (9) Image acquisition: DAPI excitation wavelength 330-380nm, emission wavelength 420nm; 488 excitation wavelength 465-495nm, emission wavelength 515-555nm; CY3 excitation wavelength 510-560nm, emission wavelength 590nm; CY5 excitation wavelength 608-648nm, emission wavelength 672-712nm.
[0207] Existing studies have shown that GPX4 is one of the important indicators for judging ferroptosis of tumor cells. GPX4 is an antioxidant enzyme that can use its catalytic activity to weaken the toxicity of peroxides and maintain the homeostasis of the tumor microenvironment. Therefore, inhibiting the activity and expression of GPX4 can promote the apoptosis of cancer cells. Fig.16 As shown, the positive expression of GPX4 is shown as red in the cytoplasm. Compared with the Model group, the effect of using free drugs alone or delivering Fc alone is not so ideal. Once the concentration of H2O2 and Fenton reaction catalyst in tumor cells is increased at the same time, the activity and expression level of GPX4 are significantly reduced. The above results show that VDF NPs can inhibit the activity and expression of GPX4, thereby killing tumor cells through the lipid peroxidation pathway.
[0208] In summary, by synthesizing an amphiphilic functional carrier, co-loading chemotherapy drugs and CDT to promote drug self-assembly to prepare nanomedicines, which can change the microenvironment in tumor cells to a certain extent and increase the concentration of H2O2 in tumor cells. At the same time, it can provide a Fenton reaction catalyst with good biocompatibility, thereby enabling the Fenton reaction to continue and improving the anti-tumor effect of chemical kinetics.
[0209] Finally, it should be noted that the above is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, it is still possible for those skilled in the art to modify the technical solutions described in the aforementioned embodiments or to make equivalent substitutions for some of the technical features therein. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. An amphiphilic functional nanocomposite, characterized in that: The nanocomposite is constructed based on an amphiphilic polymer as a carrier, and loaded with chemotherapeutic drugs and CDT-promoting drugs by an emulsification-solvent evaporation method; wherein the amphiphilic polymer has a structure shown in the following formula (I): In formula (I), n, x, y, m, and k are all natural numbers, n=10-500, x=100-300, y=150-400, m=1-500, and k=1-500; R is H, for 2. The amphiphilic functional nanocomposite according to claim 1, characterized in that: In step 1), the mass ratio of the amphiphilic polymer:chemotherapeutic drug:CDT promoting drug is 5-20:0.02-0.1:
1.
3. The amphiphilic functional nanocomposite according to claim 2, characterized in that: The chemotherapy drug is selected from one or more of DOX, cisplatin, and dihydroartemisinin.
4. The amphiphilic functional nanocomposite according to claim 2, characterized in that: The CDT promoting drug is selected from one or more of VP, β-lapachone and juglone.
5. A method for preparing the amphiphilic functional nanocomposite according to any one of claims 1 to 4, characterized in that: The specific steps are as follows: Step 1) Synthesis of amphiphilic polymer; Step 2) dissolving the amphiphilic polymer obtained in step 1) in pure water, dissolving it with ultrasonic aid until it is completely dissolved, cooling it to room temperature, and then adding an organic solvent containing a chemotherapeutic drug and a CDT-promoting drug to react while stirring in an ice bath, the reaction temperature is 25-100° C., and the reaction time is 4-72 hours; Step 3) removing the organic solvent from the reactant obtained in step 2), ultrasonicating, and performing two-stage centrifugation to obtain an amphiphilic functional nanocomposite.
6. The preparation method according to claim 5, characterized in that: In step 1), the process of synthesizing the amphiphilic polymer is as follows: Step 1: Synthesis of DeX-CHO; Step 2: Synthesis of Dex-CMCS conjugates; Step 3: Synthesis of CMCS-Dex-CHO; Step 4: Synthesis of 6-aminohexanoylferrocene; Step 5: Synthesis of Fc-Dex-CMCS conjugate.
7. The preparation method according to claim 6, characterized in that: In the first step, the raw material contains an oxidant, and the molar ratio of the dextran (Dex) to the oxidant is 1:1-10; the molecular weight of the dextran (Dex) is 2-100 kDa.
8. The preparation method according to claim 6, characterized in that: In the second step, the raw materials include carboxymethyl chitosan and a reducing agent, the molar ratio of the carboxymethyl chitosan:Dex-CHO is 0.5-5:1; the molar ratio of the carboxymethyl chitosan and the reducing agent is 1:1-10; and the molecular weight of the carboxymethyl chitosan is 2-100 kDa.
9. The preparation method according to claim 6, characterized in that: In the third step, the raw material contains an oxidant, and the molar ratio of Dex-CMCS to the oxidant is 1:20-1:
200.
10. The preparation method according to claim 6, characterized in that: In the fourth step, the raw materials include Boc-6-aminocaproic acid and ferrocene, and the molar ratio of Boc-6-aminocaproic acid to ferrocene is 0.5-5:
1.
11. The preparation method according to claim 6, characterized in that: In the fifth step, the molar ratio of CMCS-Dex-CHO to 6-aminohexanoylferrocene is 1:20-200.
12. Use of the amphiphilic functional nanocomplex according to any one of claims 1 to 4 in the preparation of a drug for treating solid tumor diseases.
13. The use according to claim 12, characterized in that: The solid tumor is pancreatic cancer.
